ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 402

Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?

Masao Sato1,2, Masao Takemura2,3, Kuniaki Saito4 and Yasuko Yamamoto4, 1Rheumatology, Matsunami General Hospital, Gifu, Japan, 2Matsunami Reserch Park, Gifu, Japan, 3Informative Laboratory Merdicine, Gifu University, Gifu, Japan, 4Human Health Science, Kyoto University, Kyoto, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers, infliximab, osteoarthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose

GP88 (progranulin; PGRN), a glycoprotein with a molecular weight of approximately 88000, is suggested to play an important role in the immune response and growth of tumors. Recently, its high affinity for the tumor necrosis factor receptor has been reported and there have been studies on its anti-inflammatory effects in autoimmune diseases. The objectives of the present study were to measure serum PGRN levels in rheumatoid arthritis (RA) patients, to analyze the changes of PGRN levels in RA patients treated with biological products, and to analyze whether PGRN is useful as a biomarker for the diagnosis and therapy evaluation of RA.

Methods

Serum PGRN levels were measured using ELISA in 149 healthy subjects (78 men and 71 women) who underwent health checkups (controls) and in 68 RA patients and 24 knee osteoarthritis (OA) patients before the start of treatment, who met the 2010 ACR/EULAR classification criteria and visited the arthritis outpatient clinic. Among RA patients who were non-responsive to methotrexate (MTX), the cryopreserved serum samples of 11 patients who were administered infliximab (IFX) were analyzed to determine the PGRN levels during the course of treatment (at baseline, week 6, week 14, week 22, and week 48).

Results

PGRN levels in the controls were 40.5 ± 14.3 ng/mL in men (mean age, 54.2 years; range, 25–68) and 41.0 ± 10.9 ng/mL in women (mean age, 51.0 years; range, 28–69), and there were no sex and age differences. PGRN levels were significantly higher in RA patients (51.2 ± 12.5 ng/mL) than in OA patients (43.9 ± 5.8 ng/mL) (p<0.01) and controls (p<0.001). Among the RA patients, 10 women and 1 man (mean age, 62.0 years; range, 27.0–78.0) received IFX treatment. MTX was administered orally at 6–8 mg/week, and IFX was administered at 3 mg/kg. Mean PGRN levels at the different time points were as follows: baseline, 45.0 ng/mL; week 6, 46.4 ng/mL; week 14, 50.8 ng/mL; week 22, 48.9 ng/mL; and week 48, 50.4 ng/mL, and there were no significant changes. Because disease activity was high at week 48 and IFX was considered ineffective, 2 cases received a different biological product. Mean PGRN levels in these 2 cases were as follows: baseline, 60.1 ng/mL; week 6, 61.3 ng/mL; week 14, 68.3 ng/mL; week 22, 74.9 ng/mL; and week 48, 79.5 ng/mL, showing an increasing tendency with the treatment course.

Conclusion

Serum PGRN levels were found to be significantly higher in RA patients than in OA patients and controls. Further, no changes in the PGRN levels were found in the group that showed a good response to IFX treatment. However, in cases resistant to IFX, PGRN levels were high when IFX was introduced, followed by an increasing tendency with the treatment course. Owing to the small number of cases in the present study, it is difficult to obtain a clear result. However, the findings showed the possibility of using PGRN levels for the differential diagnosis of RA patients and the therapy evaluation of IFX.


Disclosure:

M. Sato,
None;

M. Takemura,
None;

K. Saito,
None;

Y. Yamamoto,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-gp88-progranulin-be-used-as-a-biomarker-for-the-diagnosis-and-therapy-evaluation-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology